Role of CYP3A enzymes in the biotransformation of triazolam in rat liver

Reference

• ABURAWI, S. M., AHMED, S. S., ELHWUEGI, A. S., SAAD, S. F. and ATTIA, A. S., 2001, Brain glycine levels in triazolam-treated albino rats. Journal of Neural Transmission, 108, 527–539.
   PubMed Web of Science ®Google Scholar
• GAUDREAULT, J., VARIN, F. and POLLACK, G. M., 1996, Anticonvulsant pharmacodynamics and disposition of triazolam in rats. Journal of Pharmaceutical Science, 85, 999–1004.
   PubMed Web of Science ®Google Scholar
• GREENBLATT, D. J., WRIGHT, C. E., VON MOLTKE, L. L., HARMATZ„ J. S., EHRENBERG, B. L., HARREL, L. M., CORBETT, K., COUNIHAN, M., TOBIAS, S. and SHADER, R. I., 1998, Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clinical Pharmacology and Therapy, 64, 237–247.
   Google Scholar
• GRIEBEL, G., PERRAULT, G. and SANGER, D. J., 1998, Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. Journal of Psychopharmacology, 12, 356–365.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, P., DANNAN, G. A., WRIGHT, S. T., MARTIN, M. V. and KAMINSKY, L. S., 1982, Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or B—naphthofiavone. Biochemistry, 21, 6019–6030.
   PubMed Web of Science ®Google Scholar
• IMAOKA, S., TERANO, Y. and FUNAE, Y., 1990, Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation. Archives of Biochemistry and Biophysics, 278, 168–178.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI, K., URASHIMA, K., SHIMADA, N. and CHIBA, K., 2002, Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochemical Pharmacology, 63, 889–896.
   PubMed Web of Science ®Google Scholar
• KOTEGAWA, T., LAURIJSSENS, B. E., VON MOLTKE, L. L., COTREAU, M. M., PERLOFF, M. D., VENKATAKRISHNAN, K., WARRINGTON, J. S., GRANDA, B. W., HARMATZ, J. S. and GREENBLATT, D. J., 2002, In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. Journal of Pharmacology and Experimental Therapeutics, 302, 1228–1237.
   PubMed Web of Science ®Google Scholar
• KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. and MEYER, U. A., 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89–96.
   PubMed Web of Science ®Google Scholar
• LAKE, B. G., 1987, Preparation and characterization of microsomal fraction for studies on xenobiotic metabolism. In K. Snell and B. Mullock (eds), Biochemical Toxicology: A Practical Approach (Oxford: IRL Press), pp. 183–215.
   Google Scholar
• LAURIJSSENS, B. E. and GREENBLATT D. J., 2002, Effect of 7-day exposure to midazolam on electroencephalogram pharmacodynamics in rats: a model to study multiple pharmacokinetic—pharmacodynamic relationships in individual animals. Journal of Pharmacy and Pharmacology, 54, 77–86.
   Google Scholar
• NAKASHIMA, K., YAMAMOTO, K., AL-DIRBASHI, 0. Y. and NAKASHIMA, M. N., 2002, Disposition of triazolam in the rat by brain microdialysis and semi-micro column high-performance liquid chromatography with UV absorbance detection. Biomedical Chromatography, 16, 219–223.
   Google Scholar
• PERLOFF, M. D., VON MOLTKE L. L. and GREENBLATT, D. J., 2003, Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression. Xenobiotica, 33, 365–377.
   Google Scholar
• PERLOFF, M. D., VON MOLTKE, L. L., COURT, M. H., KOTEGAWA, T., SHADER, R. I. and GREENBLATT, D. J., 2000, Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. Journal of Pharmacology and Experimental Therapeutics, 292, 618–628.
   PubMed Web of Science ®Google Scholar
• STRESSER, D. M., BROUDY, M. I., Ho, T., CARGILL, C. E., BLANCHARD, A. P., RAMAN SHARMA, DANDENEAU, A. A., GOODWIN, J. J., TURNER, S. D., ERVE, J. C. L., PATTEN, C. J., DEHAL, S. S. and CRESPI, C. L., 2004, Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metabolism and Disposition, 32, 105–112.
   Google Scholar
• VENKATAKRISHNAN, K., VON MOLTKE L. L. and GREENBLATT D. J., 2000, Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance. Clinical Pharmacokinetics, 38, 111–180.
   Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., GRANDA, B. W., GIANCARLO, G. M., DUAN, S. X., DAILY, J. P., HARMATZ, J. S. and SHADER, R. I., 2001, Inhibition of human cytochrome P450 isoforms by non-nucleoside reverse transcriptase inhibitors. Journal of Clinical Pharmacology, 41, 85–91.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S., DUAN, S. X., HARREL, L. M., COTREAU-BIBBO, M. M., PRITCHARD, G. A., WRIGHT, C. E. and SHADER, R. I., 1996, Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. Journal of Pharmacology and Experimental Therapeutics, 276, 370–379.
   Google Scholar
• VOORMAN, R. L., MAIO, S. M., PAYNE, N. A., ZHAO, Z., KOEPLINGER, K. A. and WANG, X., 1998, Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. Journal of Pharmacology and Experimental Therapeutics, 287, 381–388.
   PubMed Web of Science ®Google Scholar
• WARRINGTON, J. S., POKU, J. W., VON MOLTKE, L. L., SHADER, R. I., HARMATZ, J. S. and GREENBLATT, D. J., 2000, Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 292, 1024–1031.
   PubMed Web of Science ®Google Scholar
• WARRINGTON, J. S., VON MOLTKE, L. L., SHADER, R. I. and GREENBLATT, D. J., 2002, In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11. Drug Metabolism and Disposition, 30, 655–657.
   PubMed Web of Science ®Google Scholar